Pluri Inc.
PLURHealthcare|Biotechnology|IL
$1.24
+0.05 (+3.82%)
Cash / Share
$0.72
Financials
Financial Snapshot
Market Cap
$13.3M
Enterprise Value
$44.7M
Revenue (TTM)
$1.0M
Net Income (TTM)
-$24.4M
Cash & Investments
$7.8M
Net Cash
-$27.1M
Free Cash Flow (TTM)
-$20.2M
Operating CF (TTM)
-$19.6M
Debt/Equity
-1.52
Cash Runway & Burn Rate
Cash on Hand
$7.8M
Quarterly Burn
$4.9M
Monthly Burn
$1.6M
Est. Runway
~1.6 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $26.1M | $29.9M | $23.7M | $46.3M | $65.0M | $55.0M | $40.2M | $30.0M | $20.6M | $7.8M | $7.8M | |
| Operating Cash Flow | -$21.6M | -$21.4M | -$29.5M | -$26.4M | -$30.9M | -$36.5M | -$22.9M | -$18.0M | -$18.2M | -$19.6M | -$19.6M | |
| Free Cash Flow | -$22.0M | -$21.7M | -$29.7M | -$26.6M | -$31.3M | -$36.8M | -$23.1M | -$18.3M | -$19.8M | -$20.2M | -$20.2M | |
| Capital Expenditure | -$378.0K | -$342.0K | -$239.0K | -$270.0K | -$373.0K | -$280.0K | -$262.0K | -$323.0K | -$1.6M | -$633.0K | -$633.0K | |
| Financing Cash Flow | $15.8M | $19.9M | $23.6M | $60.9M | $61.4M | $7.5M | $8.0M | $8.8M | $9.5M | $7.0M | $7.0M |
R&D Spending
R&D (TTM)
$15.1M
R&D Intensity
1489.8%
R&D Growth vs Prior
-1.1%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $50.0K | $54.0K | $23.0K | $0.00 | $234.0K | $287.0K | $326.0K | $1.3M | $1.0M | $1.0M | |
| R&D Expense | $21.1M | $22.6M | $24.6M | $20.1M | $30.1M | $24.4M | $15.7M | $12.4M | $12.9M | $15.3M | $15.1M | |
| R&D % of Revenue | — | 45258.0% | 45529.6% | 87495.7% | — | 10417.5% | 5486.1% | 3817.8% | 961.9% | 1506.5% | 1489.8% | |
| SG&A | $6.9M | $11.2M | $9.2M | $7.8M | $20.6M | $17.4M | $11.8M | $10.0M | $10.0M | $10.3M | $9.9M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $50.0K | $54.0K | $23.0K | $0.00 | $234.0K | $287.0K | $326.0K | $1.3M | $1.0M | $1.0M | |
| Cost of Revenue | $2.2M | $2.0K | $2.0K | $1.6M | $1.4M | $1.1M | $9.0K | $4.0K | $682.0K | $563.0K | $563.0K | |
| Gross Profit | -$2.2M | $48.0K | $52.0K | -$1.5M | -$1.4M | -$819.0K | $278.0K | $322.0K | $654.0K | $453.0K | $453.0K | |
| R&D | $21.1M | $22.6M | $24.6M | $20.1M | $30.1M | $24.4M | $15.7M | $12.4M | $12.9M | $15.3M | $15.1M | |
| SG&A | $6.9M | $11.2M | $9.2M | $7.8M | $20.6M | $17.4M | $11.8M | $10.0M | $10.0M | $10.3M | $9.9M | |
| Operating Income | -$28.0M | -$33.7M | -$35.5M | -$29.5M | -$50.6M | -$41.6M | -$27.2M | -$22.2M | -$22.2M | -$24.9M | -$25.0M | |
| Interest Expense | $0.00 | $937.0K | $29.0K | $196.0K | $78.0K | $887.0K | $843.0K | $866.0K | $873.0K | -$932.0K | $932.0K | |
| Pretax Income | -$27.8M | -$26.1M | -$35.3M | -$29.2M | -$49.9M | -$41.4M | -$28.9M | -$21.3M | -$23.3M | -$25.4M | -$25.4M | |
| Net Income | -$27.8M | -$26.1M | -$35.3M | -$29.2M | -$49.9M | -$41.2M | -$28.3M | -$20.9M | -$22.6M | -$23.8M | -$24.4M | |
| EPS (Diluted) | -25.45 | -19.74 | -23.20 | -12.80 | -14.19 | -10.24 | -6.18 | -3.99 | -3.56 | -2.44 | -2.45 | |
| EBITDA | -$25.6M | -$24.1M | -$33.3M | -$27.4M | -$48.4M | -$39.4M | -$27.7M | -$20.2M | -$22.1M | -$24.4M | -$24.0M | |
| Shares Out. (M) | 1.09 | 1.32 | 1.54 | 2.27 | 3.51 | 4.02 | 4.58 | 5.24 | 6.34 | 9.74 | 10.82 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.7M | $8.8M | $4.1M | $8.8M | $31.2M | $9.8M | $5.4M | $6.8M | $5.9M | $3.5M | $3.5M | |
| Short-Term Investments | $21.4M | $21.1M | $19.6M | $37.5M | $33.7M | $45.2M | $34.8M | $23.2M | $14.7M | $4.3M | $4.3M | |
| Total Current Assets | $29.0M | $32.0M | $26.4M | $48.5M | $67.4M | $57.7M | $41.4M | $31.1M | $22.1M | $8.7M | $8.7M | |
| Total Assets | $37.5M | $39.0M | $31.3M | $65.5M | $93.5M | $68.1M | $50.8M | $39.5M | $38.7M | $24.9M | $24.9M | |
| Total Current Liabilities | $5.4M | $8.5M | $8.2M | $8.0M | $11.5M | $6.8M | $5.6M | $4.5M | $32.3M | $32.7M | $32.7M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $23.9M | $21.7M | $23.5M | $24.0M | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $7.3M | $10.5M | $9.5M | $9.4M | $36.4M | $35.9M | $35.5M | $34.1M | $39.5M | $42.3M | $42.3M | |
| Stockholders' Equity | $30.3M | $28.5M | $21.8M | $56.1M | $57.2M | $30.0M | $13.4M | $96.0K | -$6.8M | -$23.0M | -$23.0M | |
| Retained Earnings | -$189.6M | -$215.7M | -$251.0M | -$280.2M | -$330.0M | -$371.3M | -$399.6M | -$420.5M | -$443.1M | -$466.9M | -$466.9M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$21.6M | -$21.4M | -$29.5M | -$26.4M | -$30.9M | -$36.5M | -$22.9M | -$18.0M | -$18.2M | -$19.6M | -$19.6M | |
| Capital Expenditure | -$378.0K | -$342.0K | -$239.0K | -$270.0K | -$373.0K | -$280.0K | -$262.0K | -$323.0K | -$1.6M | -$633.0K | -$633.0K | |
| Free Cash Flow | -$22.0M | -$21.7M | -$29.7M | -$26.6M | -$31.3M | -$36.8M | -$23.1M | -$18.3M | -$19.8M | -$20.2M | -$20.2M | |
| Investing Cash Flow | $4.3M | $5.6M | $1.2M | -$30.5M | -$7.3M | $11.8M | $9.7M | $10.6M | $8.0M | $9.9M | $9.9M | |
| Financing Cash Flow | $15.8M | $19.9M | $23.6M | $60.9M | $61.4M | $7.5M | $8.0M | $8.8M | $9.5M | $7.0M | $7.0M | |
| Issuance of Stock | $15.7M | $18.6M | $23.5M | $58.2M | $36.6M | $0.00 | $8.0M | $91.0K | $9.6M | $6.3M | $6.3M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $24.4M | -$2.2M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $3.7M | $6.5M | $5.1M | $2.6M | $14.0M | $8.9M | $4.0M | $2.6M | $2.1M | $3.7M | $3.7M | |
| Net Change in Cash | -$1.5M | $4.1M | -$4.7M | $4.0M | $22.6M | -$20.4M | -$5.2M | $1.4M | -$475.0K | -$2.6M | -$2.7M |
Dilution Tracker
Shares outstanding grew 177.3% over 5 years — significant dilution
Shares Outstanding
11M
5-Year Share Growth
+177.3%
Stock Issuance (TTM)
$6.3M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1.09 | 1.32 | 1.54 | 2.27 | 3.51 | 4.02 | 4.58 | 5.24 | 6.34 | 9.74 | 10.82 | |
| Change vs Prior % | — | 21.0% | 16.6% | 47.5% | 54.5% | 14.5% | 13.9% | 14.4% | 20.9% | 53.8% | 11.1% | |
| Stock Issuance | $15.7M | $18.6M | $23.5M | $58.2M | $36.6M | $0.00 | $8.0M | $91.0K | $9.6M | $6.3M | $6.3M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $3.7M | $6.5M | $5.1M | $2.6M | $14.0M | $8.9M | $4.0M | $2.6M | $2.1M | $3.7M | $3.7M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | 96.0% | 96.3% | -6726.1% | — | -350.0% | 96.9% | 98.8% | 49.0% | 44.6% | 44.6% | |
| Operating Margin % | — | -67462.0% | -65800.0% | -128156.5% | — | -17774.8% | -9493.4% | -6796.9% | -1659.9% | -2454.5% | -2455.9% | |
| Net Margin % | — | -52252.0% | -65383.3% | -126747.8% | — | -17624.8% | -9867.9% | -6407.4% | -1690.3% | -2344.6% | -2406.0% | |
| EBITDA Margin % | — | -48216.0% | -61750.0% | -119069.6% | — | -16852.1% | -9645.3% | -6204.0% | -1651.6% | -2404.2% | -2362.6% | |
| FCF Margin % | — | -43444.0% | -54985.2% | -115821.7% | — | -15718.4% | -8055.4% | -5627.0% | -1484.2% | -1990.3% | -1990.3% | |
| ROE % | -91.9% | -91.6% | -161.8% | -52.0% | -87.3% | -137.3% | -212.1% | -21758.3% | 330.1% | 103.4% | 144.6% | |
| ROA % | -74.1% | -67.1% | -112.8% | -44.5% | -53.3% | -60.6% | -55.8% | -52.8% | -58.4% | -95.8% | -98.3% | |
| ROIC % | -86.6% | -110.9% | -153.1% | -50.3% | -61.2% | -67.2% | -59.5% | -62.2% | -64.6% | -121.0% | -121.1% | |
| R&D / Revenue % | — | 45258.0% | 45529.6% | 87495.7% | — | 10417.5% | 5486.1% | 3817.8% | 961.9% | 1506.5% | 1489.8% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -100.0% | 0.0% | 8.0% | -57.4% | -100.0% | 0.0% | 22.6% | 13.6% | 309.8% | -24.0% | |
| Gross Profit | -179.3% | 102.2% | 8.3% | -3075.0% | 11.4% | 40.2% | 133.9% | 15.8% | 103.1% | -30.7% | |
| Operating Income | -20.2% | -20.4% | -5.3% | 17.0% | -71.7% | 17.8% | 34.5% | 18.7% | -0.1% | -12.5% | |
| Net Income | -19.7% | 6.1% | -35.1% | 17.4% | -71.1% | 17.3% | 31.3% | 26.2% | -8.1% | -5.5% | |
| EPS (Diluted) | -8.9% | 22.4% | -17.5% | 44.8% | -10.9% | 27.8% | 39.6% | 35.4% | 10.8% | 31.5% | |
| Operating Cash Flow | -16.7% | 1.1% | -37.8% | 10.5% | -17.2% | -18.1% | 37.4% | 21.2% | -1.1% | -7.6% | |
| Free Cash Flow | -8.5% | 1.2% | -36.7% | 10.3% | -17.4% | -17.6% | 37.1% | 20.7% | -8.1% | -2.0% | |
| R&D Expense | 7.7% | 7.3% | 8.6% | -18.1% | 49.4% | -18.9% | -35.4% | -21.0% | 3.3% | 19.1% | |
| SG&A Expense | 6.8% | 61.6% | -18.2% | -14.8% | 163.4% | -15.1% | -32.5% | -14.8% | -0.5% | 3.2% | |
| Total Assets | -18.3% | 3.8% | -19.6% | 109.3% | 42.7% | -27.2% | -25.4% | -22.2% | -2.1% | -35.7% | |
| Book Value / Share | -27.9% | -22.1% | -34.3% | 74.3% | -34.0% | -50.8% | -58.3% | -69.1% | -113.2% | -1210.8% | |
| Debt | 0.0% | 0.0% | 0.0% | 0.0% | 1451.0% | 17.2% | 3.8% | -1.0% | 15.0% | 2.5% | |
| Diluted Shares | 9.9% | 21.0% | 16.6% | 47.5% | 54.5% | 14.5% | 13.9% | 14.4% | 20.9% | 53.8% |
Valuation
P/E (TTM)At Loss
P/S13.12
10Y Low / Med / High20.04 / 169.21 / 6995.13
P/B-0.58
10Y Low / Med / High1.32 / 3.34 / 314.40
EV/EBITDAAt Loss
EV/Revenue44.01
10Y Low / Med / High44.55 / 250.54 / 6680.35
P/FCFAt Loss
Intrinsic Value Models (per share)
Cash / Share
$0.72
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -4.02 | -4.94 | -2.03 | -5.52 | -2.23 | -0.96 | -1.04 | -1.44 | -1.39 | -0.86 | -0.50 | |
| P/S Ratio | 0.00 | 2582.50 | 1347.82 | 6995.13 | 0.00 | 169.21 | 102.18 | 92.58 | 23.48 | 20.04 | 13.12 | |
| P/B Ratio | 3.70 | 4.53 | 3.34 | 2.87 | 1.95 | 1.32 | 2.20 | 314.40 | -4.58 | -0.88 | -0.58 | |
| EV/EBITDA | -4.19 | -4.99 | -2.06 | -5.61 | -2.16 | -1.49 | -1.95 | -2.62 | -2.70 | -2.12 | -1.86 | |
| EV/Revenue | 0.00 | 2406.08 | 1271.79 | 6680.35 | 0.00 | 250.54 | 187.70 | 162.61 | 44.55 | 50.93 | 44.01 |
Analyst Estimates & Quality
Altman Z-Score
-30.45
Distress
Piotroski F-Score
2
Weak
Forward Estimates (consensus)
| Metric | FY2027 |
|---|---|
| Revenue | $10.2M |
| Net Income | -$18.5M |
| EPS | $-1.90 |
| # Analysts (EPS) | 1 |